Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Chih Ho

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
American Journal of Ophthalmology|October 3, 2025
Management of Retinopathy of Prematurity in the Anti-VEGF Era: Consensus and Recommendations From the Taiwan Pediatric Retina (TPR) GroupTso-Ting Lai, Yen-Chih Chen, Sheng-Chu Chi, et al.
Liver Cancer|February 12, 2024
HBV DNA Integration into Telomerase or MLL4 Genes and TERT Promoter Point Mutation as Three Independent Signatures in Subgrouping HBV-Related HCC with Distinct FeaturesChiao-Ling Li, Chia-Lang Hsu, You-Yu Lin, et al.
Japanese Journal of Ophthalmology|December 10, 2025
Use of brolucizumab in refractory neovascular age-related macular degeneration: characteristics and biomarkers of intraocular inflammation from an Asian real-world studyChun Pao Chang, Yih-Shiou Hwang, Hung-Da Chou, et al.
Orphanet Journal of Rare Diseases|April 4, 2019
Methylmalonic acidemia/propionic acidemia - the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groupsTzu-Hung Chu, Yin-Hsiu Chien, Hsiang-Yu Lin, et al.
Journal of Hepatology|March 24, 2009
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosageChun-Jen Liu, Po-Huang Lee, Deng-Yn Lin, et al.
World Journal of Gastroenterology|August 30, 2014
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceChun-Jen Liu, Juliana Chang, Po-Huang Lee, et al.
Hepatology (Baltimore, Md.)|October 12, 2013
Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitmentChi-Kuan Chen, Ching-Yao Yang, Kuo-Tai Hua, et al.
Hepatology Communications|June 9, 2018
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis BShiu-Feng Huang, Il-Chi Chang, Chih-Chen Hong, et al.
The Journal of Experimental Medicine|July 16, 2025
Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophagesXiaoyun Li, Sofie Hedlund Møller, Jaeoh Park, et al.
Clinical and Molecular Hepatology|August 4, 2025
Taiwan Liver Cancer Association Management Consensus Guidelines for Intermediate Stage Hepatocellular CarcinomaI-Cheng Lee, Hung-Wei Wang, Wei Teng, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
American Journal of Ophthalmology|October 3, 2025
Management of Retinopathy of Prematurity in the Anti-VEGF Era: Consensus and Recommendations From the Taiwan Pediatric Retina (TPR) GroupTso-Ting Lai, Yen-Chih Chen, Sheng-Chu Chi, et al.
Liver Cancer|February 12, 2024
HBV DNA Integration into Telomerase or MLL4 Genes and TERT Promoter Point Mutation as Three Independent Signatures in Subgrouping HBV-Related HCC with Distinct FeaturesChiao-Ling Li, Chia-Lang Hsu, You-Yu Lin, et al.
Japanese Journal of Ophthalmology|December 10, 2025
Use of brolucizumab in refractory neovascular age-related macular degeneration: characteristics and biomarkers of intraocular inflammation from an Asian real-world studyChun Pao Chang, Yih-Shiou Hwang, Hung-Da Chou, et al.
Orphanet Journal of Rare Diseases|April 4, 2019
Methylmalonic acidemia/propionic acidemia - the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groupsTzu-Hung Chu, Yin-Hsiu Chien, Hsiang-Yu Lin, et al.
Journal of Hepatology|March 24, 2009
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosageChun-Jen Liu, Po-Huang Lee, Deng-Yn Lin, et al.
World Journal of Gastroenterology|August 30, 2014
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceChun-Jen Liu, Juliana Chang, Po-Huang Lee, et al.
Hepatology (Baltimore, Md.)|October 12, 2013
Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitmentChi-Kuan Chen, Ching-Yao Yang, Kuo-Tai Hua, et al.
Hepatology Communications|June 9, 2018
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis BShiu-Feng Huang, Il-Chi Chang, Chih-Chen Hong, et al.
The Journal of Experimental Medicine|July 16, 2025
Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophagesXiaoyun Li, Sofie Hedlund Møller, Jaeoh Park, et al.
Clinical and Molecular Hepatology|August 4, 2025
Taiwan Liver Cancer Association Management Consensus Guidelines for Intermediate Stage Hepatocellular CarcinomaI-Cheng Lee, Hung-Wei Wang, Wei Teng, et al.
Pageof 15